Urgent.News

600+ sources. One page. See who else covered it.

Editions

Finance & Markets

Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology

Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast and gastric cancers BOSTON and LIEGE, Belgium, Aug. 10, 2026 (GLOBE NEWSWIRE) — Curium™ a leading global radiopharmaceutical company, announced that it has completed the…

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Finance & Markets

More from Monday 10 August →